FOCUSED ON CURES

Excision is developing CRISPR-based therapies
to cure viral infectious diseases and improve the lives of chronically ill patients.


LEARN MORE

WHO WE ARE


We are an experienced and passionate group of researchers and drug developers advancing CRISPR-based therapies to commercialization. Excision’s technology demonstrated significant advances in infectious disease research including for the first time, eliminating HIV from an infected animal’s genome.


OUR MISSION


2015

Excision’s foundational technologies were discovered in the Khalili lab at Temple University School of Medicine and the Doudna lab at UC Berkeley. Excision was founded around bringing these technologies to patients.

2016

Leveraging these novel and industry-leading gene editing platforms, the Excision team demonstrated the first in-vitro proof of concept of removing, or excising, viral genomes from infected cells.

2017

The Excision technology demonstrated the first in-vivo removal of viral genomes from animals.

2019

Researchers eliminated HIV from infected animals’ genomes for the first time.
 
 

UNPARALLELED RESEARCH
ENDLESS POSSIBILITIES

The Excision BioTherapeutics team includes some of the top biochemistry, chemistry and molecular biology experts with concentrations in the fields of retrovirology, virology, viral genetics, bioinformatics and advanced drug delivery.

AREAS OF FOCUS:

Human Immunodeficiency Virus-1 Therapeutics
JC Virus and Progressive Multifocal Leukoencephalopathy
Herpes Simplex Virus 1 and 2 Therapeutics​
Hepatitis B Virus Therapeutics
Advanced DNA and Biologic Delivery Systems

WHAT PEOPLE ARE SAYING


Researchers find new ways to kick out HIV from Infected Cells

Time Magazine

Genome Editing Cuts Out HIV

The Scientist

How Many People Have Been Cured of AIDS

NBC News

Health: Temple University Researchers Successfully Eliminate HIV Virus in Human Cells

CBS

 

CORPORATE

PHILADELPHIA